Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

Clinical trial NCT07070713 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07070713
Sponsor: Fujian Cancer Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Colorectal Cancer With Left-sided Primary Tumor Immunotherapy

Start date: 2025-07-30
Primary completion: 2028-02-28
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.